Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

被引：2
|
作者：
Chen, Ronald C.
Feuilly, Marion
Meng, Jie
Lister, Johanna
Marteau, Florence
Morris, Michael J.
George, Daniel J.
Choueiri, Toni K.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] IPSEN Pharma SAS, Boulogne, France
[3] Analyt LASER Intl, Lorrach, Germany
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Duke Univ, Durham, NC USA
[6] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4556
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
    Brufsky, A. M.
    Bardia, A.
    Sedrak, M. S.
    Loibl, S.
    Tolaney, S. M.
    Punie, K.
    Hurvitz, S. A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Piccart, M.
    Dasgupta, A.
    Kaushik, A. G.
    Lai, C.
    Shi, L.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S382 - S383
  • [42] A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE AND TOXICITY (Q-TWIST) ANALYSIS COMPARING NIVOLUMAB AND THERAPY OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) (CHECKMATE 141)
    Simpson, S.
    Cocks, K.
    Contente, M.
    DeRosa, M.
    Taylor, F.
    Shaw, J. W.
    VALUE IN HEALTH, 2017, 20 (09) : A450 - A450
  • [43] Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Lin, Tara
    Uy, Geoffrey L.
    Ryan, Robert J.
    Faderl, Stefan
    Lancet, Jeffrey E.
    BLOOD, 2020, 136
  • [44] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Ashaye, Ajibade
    Shi, Ling
    Aldoss, Ibrahim
    Montesinos, Pau
    Vachhani, Pankit
    Papayannidis, Cristina
    Leonard, Jessica T.
    Baer, Maria R.
    Ribera, Josep-Maria
    Mccloskey, James
    Wang, Jianxiang
    Gao, Sujun
    Rane, Deepali
    Guo, Shien
    BLOOD, 2024, 144 : 2825 - 2826
  • [46] Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO plus CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.
    Cella, David
    Choueiri, Toni K.
    Blum, Steven I.
    Ejzykowicz, Flavia
    Wallace, Joel
    Zhang, Joshua
    Simsek, Burcin
    Ivanescu, Cristina
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
    Stintzing, Sebastian
    Tabernero, Josep
    Satoh, Taroh
    Dasari, Arvind
    Lonardi, Sara
    Eng, Cathy
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Kasper, Stefan
    Arnold, Dirk
    Basic, Edin
    Granold, Matthias
    Petschulies, Marco
    Wu, Liwen
    Chen, Lucy
    Yang, Zhao
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 116 - 116
  • [48] Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma.
    Kersten, Marie Jose
    Qiao, Yao
    Shah, Ruchit
    Solem, Caitlyn
    Snider, Julia
    To, Christina Ann
    Cheng, Paul
    Spooner, Clare
    Perales, Miguel-Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
    Stintzing, Sebastian
    Tabernero, Josep
    Satoh, Taroh
    Dasari, Arvind
    Lonardi, Sara
    Eng, Cathy
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Kasper, Stefan
    Arnold, Dirk
    Basic, Edin
    Granold, Matthias
    Petschulies, Marco
    Wu, Liwen
    Chen, Lucy F.
    Yang, Zhao
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis comparing nab-paclitaxel plus carboplatin (nab-PC) with solvent-based paclitaxel plus carboplatin (sb-PC) in first-line advanced non-small cell lung cancer (NSCLC)
    Langer, Corey J.
    Hirsh, Vera
    Wan, Yin
    Lin, Fang-Ju
    Whiting, Scott
    Ong, Teng Jin
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345